Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment

Diagnostic Microbiology and Infectious Disease

Volumn 58, Issue 3, 2007, Pages 337-344

  DeRyke, C Andrew ^a   Kuti, Joseph L ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Antibiotic; Bacterial resistance; Pharmacodynamics; Susceptibility

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; COMPARTMENT MODEL; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; KLEBSIELLA; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MODEL; MONTE CARLO METHOD; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RECOMMENDED DRUG DOSE;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; ESCHERICHIA COLI; GRAM-NEGATIVE AEROBIC RODS AND COCCI; HUMANS; KLEBSIELLA; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MONTE CARLO METHOD; PSEUDOMONAS AERUGINOSA;

EID: 34347339333     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2007.01.004     Document Type: Article

References (30)

1. Ambrose P.G., Bhavnani S.G., Jones R.N., Craig W.A., and Dudley M.A. Use of Pharmacokinetic-Pharmacodynamic and Monte Carlo Simulation as Decision Support for the Re-evaluation of NCCLS Cephem Susceptibility Breakpoints for Enterobacteriaceae, Abstr. A-138. Programs and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington (DC): American Society of Microbiology (2004)
2. Ambrose P.G. Antimicrobial susceptibility breakpoints: PK-PD and susceptibility breakpoints. Treat. Respir. Med. 4 Suppl 1 (2005) 5-11
3. Ambrose P.G. Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future. Pharmacotherapy 26 (2006) 129-134
4. Bland J.M., and Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1 (1986) 307-310
5. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, 15th Information Supplement. Document M100-S15. Wayne (PA): CLSI: (2005)
6. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26 (1998) 1-10
7. DeRyke CA, Kuti JL, Nicolau DP (in press) Pharmacodynamic target attainment of 6 intravenous β-lactams and 2 fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from U.S. Intensive Care Units during 2004. Pharmacother.
8. Drusano G.L., Plaisance K.I., Forrest A., Bustamante C., Devlin A., Standiford H.C., and Wade J.C. Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients. Antimicrob. Agents Chemother. 31 (1987) 1420-1422
9. Drusano G.L., Preston S.L., Hardalo C., Hare R., Banfield C., Andes D., Vesga O., and Craig W.A. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45 (2001) 13-22
10. Drusano G.L. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat. Rev. Microbiol. 2 (2004) 289-300
11. Dudley M.N., and Ambrose P.G. Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: ready for prime time. Curr. Opin. Microbiol. 3 (2000) 515-521
12. Forrest A., Nix D.E., Ballow C.H., Goss T.F., Birmingham M.C., and Schentag J.J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37 (1993) 1073-1081
13. Jones R.N., Craig W.A., Ambrose P.G., Dudley M.N., and Pottumarthy S. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases. Diagn. Microbiol. Infect. Dis. 52 (2005) 235-246
14. Joynt G.M., Lipman J., Gomersall C.D., Young R.J., Wong E.L., and Gin T. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J. Antimicrob. Chemother. 47 (2001) 421-429
15. Kiffer C.R., Mendes C., Kuti J.L., and Nicolau D.P. Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002. Diagn. Microbiol. Infect. Dis. 49 (2004) 109-116
16. Kuti J.L., Dandekar P.K., Nightingale C.H., and Nicolau D.P. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J. Clin. Pharmacol. 43 (2003) 1116-1123
17. Kuti J.L., Nightingale C.H., and Nicolau D.P. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002. Antimicrob. Agents Chemother. 48 (2004) 2464-2470
18. Kuti J.L., and Nicolau D.P. Making the most of surveillance studies: summary of the OPTAMA Program. Diagn. Microbiol. Infect. Dis. 53 (2005) 281-287
19. Li C., Kuti J.L., Nightingale C.H., and Nicolau D.P. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J. Clin. Pharmacol. 46 (2006) 1171-1178
20. Lodise T.P., Lomaestro B., Rodvold K.A., Danziger L.H., and Drusano G.L. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob. Agents Chemother. 48 (2004) 4718-4724
21. Masterton R.G., Kuti J.L., Turner P.J., and Nicolau D.P. The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe. J. Antimicrob. Chemother. 55 (2005) 71-77
22. Mouton J.W., Dudley M.N., Cars O., Derendorf H., and Drusano G.L. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. 55 (2005) 601-607
23. Newcombe R.G. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat. Med. 17 (1998) 857-872
24. Rebuck J.A., Fish D.N., and Abraham E. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy 22 (2002) 1216-1225
25. Rhomberg P.R., Fritsche T.R., Sader H.S., and Jones R.N. Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004). J. Chemother. 17 (2005) 459-469
26. Tam V.H., McKinnon P.S., Akins R.L., Drusano G.L., and Rybak M.J. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob. Agents Chemother. 47 (2003) 1853-1861
27. Turnidge J.D. The pharmacodynamics of beta-lactams. Clin. Infect. Dis. 27 (1998) 10-22
28. Walker R., Andes D., Conklin J., Ebert S., and Craig W.A. Pharmacodynamic Activities of Meropenem in an Animal Infection Model, abstr. A-91. Programs and Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington (DC): American Society for Microbiology (1994)
29. Wright D.H., Brown G.H., Peterson M.L., and Rotschafer J.C. Application of fluoroquinolone pharmacodynamics. J. Antimicrob. Chemother. 46 (2000) 669-683
30. Young R.J., Lipman J., Gin T., Gomersall C.D., Joynt G.M., and Oh T.E. Intermittent bolus dosing of ceftazidime in critically ill patients. J. Antimicrob. Chemother. 40 (1997) 269-273